Total pharma venture financing deals in January 2019 worth $1.99bn were announced globally, according to GlobalData’s deals database.
Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 6.4% over the previous month and a rise of 11.3% when compared with the last 12-month average, which stood at $1.79bn.
Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $1.43bn. At the country level, the United States topped the list in terms of deal value at $1.43bn.
In terms of volumes, North America emerged as the top region for pharma venture financing deals globally, followed by Europe and then Asia-Pacific.
The top country in terms of venture financing deals activity in January 2019 was the United States with 47 deals, followed by China with eight and the United Kingdom with six.
Pharma venture financing deals in January 2019: Top deals
The top five pharma venture financing deals accounted for 34.6% of the overall value during January 2019.
The combined value of the top five pharma venture financing deals stood at $689.2m, against the overall value of $1.99bn recorded for the month.
The top announced pharma venture financing deal tracked by GlobalData in January 2019 was Aisling Capital , American International Group, Cormorant Capital, Hercules Capital, Kohlberg Kravis Roberts & Co, Perceptive Advisors, Sequoia Capital Operations and Viking Global Investors’ $299.2m venture financing of BridgeBio Pharma.
In second place was Boyu Capital, Celgene, FountainVest Partners, Qiming Venture Partners, Taikang Asset Management, TF Capital and WuXi PharmaTech Corporate Venture’s venture financing of Antengene for $120m and in third place was CMB International Capital and OrbiMed Asia Partners’ $100m venture financing of Apollomics.
Baron Fund, Bill & Melinda Gates Foundation, Deerfield Management, GV Management Co, Qiming Venture Partners and WuXi PharmaTech Corporate Venture Fund’s $85m venture financing of Schrodinger and New Enterprise Associates, Nextech Invest, Perceptive Advisors, RA Capital Management and Invus Group’s venture financing of Black Diamond Therapeutics for $85m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.